CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $200,000 | -4.8% | 3,204 | +15.8% | 0.02% | -4.8% |
| Q4 2021 | $210,000 | -9.9% | 2,767 | +92.7% | 0.02% | -22.2% |
| Q2 2021 | $233,000 | +4.0% | 1,436 | -21.8% | 0.03% | +8.0% |
| Q1 2021 | $224,000 | -29.3% | 1,837 | -11.8% | 0.02% | -34.2% |
| Q4 2020 | $317,000 | +28.9% | 2,082 | -62.0% | 0.04% | -9.5% |
| Q3 2018 | $246,000 | -4.7% | 5,485 | +26.9% | 0.04% | -31.1% |
| Q2 2018 | $258,000 | – | 4,323 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |